In 2018, the global biosimilars market attained a value of $6.0 billion and is projected to register a 29.6% CAGR during the forecast period (2019–2024).
The market is registering growth due to the inexpensive nature of biosimilar drugs, increasing geriatric population, rising research & development (R&D) investment by biopharmaceutical companies and extensive pipeline of biosimilars, and rising prevalence of chronic diseases. Generic equivalents of biologics are referred to as biosimilars. They are highly similar and comparable version of an approved biologic medicine and undergo clinical trials for demonstrating efficacy and safety.
When technology is taken into consideration, the biosimilars market is divided into electrophoresis, monoclonal antibody (mAb), nuclear magnetic resonance, recombinant deoxyribonucleic acid, and bioassays. Out of these, the mAb technology dominated the market during the historical period 2014–2018 and is expected to account for the major share of the market during the forecast period as well. This is because of the increasing utilization of mAbs and technological advancements in the field. The division is further predicted to grow at the fastest pace during the forecast period.
On the basis of indication, the biosimilars market is categorized into growth hormone deficiency, infectious diseases, chronic diseases, auto-immune diseases, blood-related disorders, rheumatology, oncology, and others (which include metabolic disorders). Out of these, the oncology category held the largest share of the market during the historical period and is further predicted to dominate the market during the forecast period. The primary reason for this is the surging incidence of cancer around the world. As per the World Health Organization (WHO), about one in every six deaths took place because of cancer in 2018.
Another major driving factor of the biosimilars market is the increasing R&D investment by biopharmaceutical companies and extensive pipeline of biosimilars. Pharmaceutical companies are considerably investing in their R&D processes, which is why several biopharmaceutical companies have biosimilars either in pipeline or are being marketed. For example, Teva Pharmaceuticals Industries Limited has two biosimilars in the pipeline, namely trastuzumab biosimilar, CT-P62 and rituximab injection, TRUXIMA. This indicates that companies are willingly investing in biologics, which is leading to the growth of the market.
Hence, the market is being driven by the rising R&D investments and growing prevalence of chronic diseases.
Personal Protective Equipment: Human Life Savers in Factories
Personal Protective Equipment Market to Register Robust Growth of 7.7% CAGR during 2020–2030
What Are the Evolving Opportunities for the Players in the Guidewires Market?
The guidewires market was able to generate $816.3 million in 2017, and it is set to reach $1,126.5 million by 2023, at a CAGR of 5.5%.
Why Is North America Largest Disposable Medical Sensors Market?
Growth drivers including the spurring demand for low-cost medical equipment and escalating incidence of hospital-acquired infections (HAIs) will propel the disposable medical sensors market at a 10.4% CAGR during the forecast period (2017–2023).
